<?xml version="1.0"?>
<?xml-stylesheet type="text/css" href="http://www.feuxdelamour.com/v4/skins/common/feed.css?303"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="fr">
		<id>http://www.feuxdelamour.com/v4/index.php?action=history&amp;feed=atom&amp;title=Little-Known_Methods_Of_Rule_With_Transducin</id>
		<title>Little-Known Methods Of Rule With Transducin - Historique des versions</title>
		<link rel="self" type="application/atom+xml" href="http://www.feuxdelamour.com/v4/index.php?action=history&amp;feed=atom&amp;title=Little-Known_Methods_Of_Rule_With_Transducin"/>
		<link rel="alternate" type="text/html" href="http://www.feuxdelamour.com/v4/index.php?title=Little-Known_Methods_Of_Rule_With_Transducin&amp;action=history"/>
		<updated>2026-07-02T07:28:00Z</updated>
		<subtitle>Historique pour cette page sur le wiki</subtitle>
		<generator>MediaWiki 1.20alpha</generator>

	<entry>
		<id>http://www.feuxdelamour.com/v4/index.php?title=Little-Known_Methods_Of_Rule_With_Transducin&amp;diff=62580&amp;oldid=prev</id>
		<title>Butane3area : Page créée avec « Risk factors for MDR P.?aeruginosa, A.?baumannii and ESBL-producing [http://www.selleckchem.com/products/Staurosporine.html PKC inhibitor] GNB were determined using univar... »</title>
		<link rel="alternate" type="text/html" href="http://www.feuxdelamour.com/v4/index.php?title=Little-Known_Methods_Of_Rule_With_Transducin&amp;diff=62580&amp;oldid=prev"/>
				<updated>2017-01-29T09:07:40Z</updated>
		
		<summary type="html">&lt;p&gt;Page créée avec « Risk factors for MDR P.?aeruginosa, A.?baumannii and ESBL-producing [http://www.selleckchem.com/products/Staurosporine.html PKC inhibitor] GNB were determined using univar... »&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Nouvelle page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;Risk factors for MDR P.?aeruginosa, A.?baumannii and ESBL-producing [http://www.selleckchem.com/products/Staurosporine.html PKC inhibitor] GNB were determined using univariate and multivariate analysis. Five hundred and eleven consecutive patients were included; ICU-acquired MDR P.?aeruginosa was diagnosed in 82 (16%) patients, A.?baumannii in 57 (11%) patients, and ESBL-producing GNB in 50 (9%) patients. Independent risk factors for ICU-acquired MDR P.?aeruginosa were prior occupant with MDR P.?aeruginosa (OR 2.3, 95% CI 1.2�C4.3, p?0.012), surgery (OR 1.9, 95% CI 1.1�C3.6, p?0.024), and prior piperacillin/tazobactam use (OR 1.2, 95% CI 1.1�C1.3, p?0.040). Independent risk factors for ICU-acquired A.?baumannii were prior occupant with A.?baumannii (OR 4.2, 95% CI 2�C8.8, p?[http://www.selleckchem.com/products/gsk126.html GSK126 manufacturer] results of a recent large international study performed in 1265 ICUs [1], infection was present in 51% of the 13?796 included patients. Infection was microbiologically confirmed in 69.8% of these patients, and MDR bacteria accounted for 44% of all bacteria. Patients with ICU-acquired infections related to MDR bacteria frequently receive inappropriate initial antibiotic treatment [2,3]. In addition, infections related to these bacteria are associated with increased morbidity and mortality [4,5]. Patients in the ICU are commonly exposed to broad-spectrum antimicrobial agents, and the ICU presents ample opportunities for the cross-transmission of MDR bacteria from patient to patient [6]. Environmental contamination with MDR bacteria occurs during the care of patients [http://en.wikipedia.org/wiki/Transducin Transducin] harbouring these bacteria [7,8]. Huang et?al. [9] performed a 20-month retrospective multicentre study to determine the risk of acquiring resistant bacteria from prior room occupants. Among patients whose prior room occupant was positive for methicillin-resistant Staphylococcus aureus (MRSA), 3.9% acquired MRSA compared with 2.9% of patients whose prior room occupant was MRSA negative (OR 1.4, p?0.04). Among patients whose prior room occupant was positive for vancomycin-resistant enterococci (VRE), these values were 4.5% and 2.8%, respectively (OR 1.4, p?0.02). Another recent study was performed during a 14-month period [10]. Weekly environmental cultures, and twice weekly patient surveillance cultures were performed in two ICUs.&lt;/div&gt;</summary>
		<author><name>Butane3area</name></author>	</entry>

	</feed>